Jon Congleton; Chief Executive Officer, Director; Mineralys Therapeutics Inc. David Rodman; Chief Medical Officer ...

Reduced baroreflex sensitivity is tied to an increased risk for dementia in older adults who do not take antihypertensive medications.

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 – – Completed enrollment in Explore-CKD Phase 2 trial and anticipate ...

The aim of this study was to perform a persistencebased pharmacoeconomic evaluation of patients receiving antihypertensive drug treatment. Specific objectives were represented by measuring ...

Vitamin D3 supplementation was associated with antihypertensive effects without significant between-dose differences among overweight older adults.

CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...

Q4 2024 Earnings Call Transcript February 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

In patients with HF with reduced ejection fraction, HTN is treated differently in comparison to patients with HF with normal ejection fraction. This article reviews the treatment of essential HTN ...

Daewoong Bio surpasses 10 billion won in antihypertensive drug sales Daewoong Bio reports significant revenue milestone in blood pressure medicine sales ...

Background Left ventricular (LV) mass is closely associated with atherosclerotic heart disease, but the mechanisms are not well defined. This study aimed to evaluate the risk factors associated with ...

Mount Carmel’s heart and vascular teams have debuted several new, highly advanced surgical procedures in Central Ohio.